They would have had to payback the $500k otherwise, so it is material.
The language seems promising too - "Once the results are reported, Bod intends to submit the dossier to the TGA for their review of what is anticipated to be the first Schedule 3 CBD product to be made available in Australia."
Ann: Updates on Phase IIB clinical trial of Schedule 3 CBD, page-5
Add BOD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| BOD (ASX) Chart |
Day chart unavailable